Drug Trial Radar · NCT06919003
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
May 30, 2031
Study completion May 30, 2032
Sponsor
- Sponsor type
- NIH
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but does not contain any active drug. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Neither you or the study doctor can choose or know which group is assigned. The primary objective is to test whether intrarenal artery C1 esterase inhibitor (C1INH) injection into the donor kidney prior to transplantation improves kidney function in recipients of high risk, deceased donor kidney transplants as measured by 12-month Estimated Glomerular Filtration Rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI)
Conditions
- Kidney Transplant
Interventions
BerinertBiological
Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
Placebo for BerinertOther
Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference between study arms in renal functionTime frame: At 12-months post-transplantation
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Kansas University Medical Center
Kansas City, Kansas · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.